Washington, DC Partner Liz Gray will be presenting, “Reacting to Scrutiny of Clinical Trial Disclosures by the SEC,” at the American Conference Institute’s 7th National Conference on Managing Legal Risks in Structuring & Conducting Clinical Trials in San Francisco on July 16.
Specifically, she will discuss:
- How FDA and SEC cooperation (Referral Process and Centralized Procedures) have affected scrutiny of clinical trial disclosures
- Complying with SEC reporting requirements pre- and post-approval
- Reconciling FDA/SEC disclaimer requirements
- Factoring in recent enforcement activities by the SEC and FDA
- Lessons learned from ImClone, TKT, ICN, and NY Executive Law 63(12)
- Disclosing clinical trial information that has been made available to the FDA but not publicly disclosed
- Determining what FDA actions to disclose and how to disclose them for accurate interpretation by the securities market
- Alleviating securities concerns: whether databank entries constitute “forward-looking statements” for investor reliance; and
- Controlling and monitoring material inside information and disclosing material facts to shareholders
Related Insights
May 22, 2026
Foley Viewpoints
New Lawsuit Tests the Limits of Donor-Advised Fund Advisory Privileges
A recent lawsuit seeking to clarify the extent of an advisor’s privileges with respect to a donor-advised fund (DAF) has been filed in…
May 22, 2026
Energy Current
FERC Just Rewrote the Rules for Natural Gas Infrastructure. Here’s What It Means.
Yesterday’s unanimous FERC vote is the most significant natural gas permitting reform in two decades — and its practical implications…
May 22, 2026
Foley Viewpoints
What the Federal Circuit’s Poultry Patent Ruling Says About 'About'
The decision does not appear to prohibit the use of terms such as "about" or "approximately." Rather, it reinforces that such terms may be acceptable where the patent record provides sufficient context for understanding the scope of the claimed range.